Use the right technology, the right biology, and the right model

ICDD's technologies for pre-clinical testing

We offer HTS and HCA industry-validated screening platforms to assess the safety and efficacy of hits and leads. The analysis of the mitochondrial function and behavior is done inside a living cell, maintaining existing mitochondrial interactions, with integrated multiplexed bioassays. Results obtained are fully supported by proper statistics and interpreted with respect to the physiological context in which the experiments take place.

Mitosafe® platform

The Mitosafe® technology is a high througput screening (HTS) platform that examines mitochondrial function in functional bioassays in which multiplexed targets are assessed at the same time.

The bioassays are done in non-permeabilized primary living cells, and require no isolation of the mitochondria. They are customizable in pertinent cell models.

Use this technology to:

  • Identify drug mechanisms of action & pharmacological activity
  • Identifiy mitochondrial liabilities
  • Improve early de-selection of hits with mitochondrial liabilities

Mitostream® platform

The Mitostream® technology is a high content analysis (HCA) platform that examines mitochondrial behavior through phenotypic outcome. It is the resultant of dynamical interactions of mitochondrial targets with targets in other cell compartments.

Mitostream also uses non-permeabilized primary living cells, with no isolation of the mitochondria required.

Use this technology to:

  • Qualify and quantify cellular adaptability
  • Identify disease signatures from patient-derived cell models
  • Establish disease-modifying property of drugs
  • Profile toxicity potential
  • Establish organ-toxicity signatures
  • Anticipate clinical tolerance at the preclinical stage

Check out which applications of our technologies best match your needs on our service pages.

Our models

ICDD has developed expertise in the development and validation of patient-derived cell models to increase results translatability. We favor primary cell models, but stem cell-derived pertinent cell models for specific diseases can also be obtained. We are also open to co-developing patient-derived disease models.

Models for efficacy testing

  • Human/rodent primary cell biobank
    • –   Fibroblasts, hepatocytes, cardiomyocytes
    • –   iPSCs, iPSCs-derived neural precursors
    • –   Variety of age/gender/ethnicity
  • Disease model
    • –   Non-alcoholic fatty liver disease model
    • –   Senescent cell model
  • CNS disease-modifying drug selection model
    • –   Patient-derived cells
    • –   Reversal of Mitoselect signature
    • –   Alzheimer (sporadic)
    • –   Huntington
    • –   Parkinson (sporadic - LRRK2+ mutation)
  • Cancer profiling
    • –   Profiling of cancer cell lines using the BBS, Redox status & mitochondrial fusion-fission dynamics readouts
    • –   Identification of drug-response elements

Models for toxicity testing

  • Identification of mitochondrial liabilities
    • –   Use of the Mitosafe® technology
    • –   BBS/BBS+ in HepG2 cells
    • –   Early preclinical hit deselection
  • Cellesis Toxicity profiling
    • –   Use of the Mitostream® technology
    • –   Lead optimization
    • –   Rank-ordering of compounds based on a quantitative scale of tolerance risks
    • –    Derisking of drug candidates (high ROI)

Use the right biology

Mitochondria

Mitochondria are present in every cell of the body. They maintain cell homeostasis, contribute to both energy and free radical production, orchestrate anti-oxidant defenses, and are essential to cell metabolism and survival. Hence, they represent a major target for drug development.

Altered mitochondrial function and behavior have been recognized in CNS diseases, cancer, metabolic diseases, and more generally in age-associated diseases. Furthermore, drug-induced modifications of mitochondrial function and behavior, when unintended, are associated with severe side effects.

Mitochondrial function and behavior are phenotypic readouts that can characterize patient-derived disease cell models, drug response, and tolerance elements.

ICDD takes into account the mitochondrion and its environment: the cell. Indeed, all analysis of mitochondrial function and behavior is done inside a living cell, maintaining existing interactions, with integrated multiplexed bioassays.

Learn more about mitochondria